Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PRO1107 |
| Synonyms | |
| Therapy Description |
PRO1107 is an antibody-drug conjugate (ADC) comprising an anti-PTK7 monoclonal antibody linked to the anti-microtubule agent monomethyl auristatin E (MMAE), which potentially induces cytotoxicity against tumor cells and demonstrates antitumor activity (Journal for ImmunoTherapy of Cancer 2023;11). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PRO1107 | PRO 1107|PRO-1107 | PRO1107 is an antibody-drug conjugate (ADC) comprising an anti-PTK7 monoclonal antibody linked to the anti-microtubule agent monomethyl auristatin E (MMAE), which potentially induces cytotoxicity against tumor cells and demonstrates antitumor activity (Journal for ImmunoTherapy of Cancer 2023;11). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06171789 | Phase Ib/II | PRO1107 | PRO1107 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |